A phase II multi-center, open-label, single-arm study to evaluate the efficacy and safety of Loncastuximab-tesirine (ZYNLONTA) used as monotherapy in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Loncastuximab tesirine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Overland ADCT BioPharma
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Aug 2022 Status changed from recruiting to active, no longer recruiting, according to an ADC therapeutics media release.
- 01 Oct 2021 New trial record